Therapeutic Drug Monitoring (TDM) of Cyclosporine Using the Area Under the Curve in Children Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Abstract

All patients Mean AUC24h 21 days (ng.h/mL) Mean C0 21 days (ng/mL) 12 581 Minimum 6531 Maximum 20168 202 Minimum 78 Maximum 430 With GVHD 12 561 p ¼ 0.98 193 p ¼ 0.64 No GVHD 12 590 205 With nephrotoxicity 12 345 p ¼ 0.611 214 p ¼ 0.360 No nephrotoxicity 12 765 193

Cyclosporine use in Hematopoietic Stem Cell Transplantation: Pharmacokinetic Approach

“…Although some studies found no difference in oral absorption profiles of gelatin capsules versus solution [3,68], one has to be cautious because total PK and pharmacodynamic equivalency may not be a fixed rule especially for adverse reactions or monitoring parameters [69][70][71][72].…”